Company intelligence / Profile preview

Optos

Dunfermline, Scotland, United Kingdom

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Optos’ UWF retinal imaging technology, including flagship devices like optomap and MonacoPro, has installed over 16,000 systems globally and imaged more than 150 million patients, supporting both routine and advanced disease detection. Clinical results published on the optomap platform show equivalence to the ETDRS gold standard for diabetic retinopathy detection and improved diagnostic workflow for age-related macular degeneration.

Therapeutic areas: NeurologyOphthalmology
Modalities: DeviceImaging
Industry: Medical Imaging

Partnerships

Amydis (Alzheimer’s diagnostic development)Verily (machine learning-enabled diabetic retinopathy solutions with Nikon)

Beyond the preview

Go deeper on Optos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optos.

Explore the full profile